Capstone Holding Corp

Capstone Holding Corp wins a North Carolina noise‑wall contract, expanding its infrastructure portfolio and boosting investor confidence while still advancing biotech innovations.

Capstone Holding Corp. hits key milestones after integrating Canadian Stone Industries, driving operational wins, sales growth, and immediate accretive gains.

Capstone Holding Corp. posts Q3 revenue growth, margin gains and a $26 M acquisition, but a low market cap and negative P/E leave investors wondering if the company’s dual‑sector model can drive long‑term growth.

Capstone Holding Corp, a biotechnology company, is facing financial struggles and market volatility, raising concerns about its growth potential and sustainability, despite its commendable mission to address under-served medical conditions.

Capstone Holding Corp is a biotechnology company pioneering the development of novel peptides and molecules to address under-served medical conditions, despite facing challenges and volatility in the industry.

Capstone Holding Corp, a biotech company in the industrials sector, has seen its stock price plummet from $16.18 to $1.29 in a year, raising concerns about its financial health and ability to deliver on its promise of developing novel peptides for u…

Capstone Holding Corp. reaffirms its 2025 financial targets of $100 million revenue and $10 million adjusted EBITDA, while accelerating its growth strategy through strategic acquisitions.

Capstone Holding Corp. reaffirms its financial targets for 2025, citing a balanced approach of organic growth and strategic acquisitions to drive revenue and EBITDA growth.

Capstone Holding Corp. reaffirms its Q1 targets and 2025 outlook, demonstrating resilience and strategic foresight amidst market volatility.